Polymyalgia rheumatica - an up-to-date review on diagnosis and management

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in those over the age of 50 years. Previously it was considered to be a benign clinical syndrome characterised by subacute onset bilateral shoulder and pelvic girdle pain and stiffness, with a corresponding rise in acute phase reactants, and distinctive rapid resolution of symptoms with the instigation of moderate doses of glucocorticoids. However, over the past decade, with the advancements and, indeed, wider application of imaging modalities in PMR, we have garnered an increased understanding of the anatomic predilection of inflammation and, subsequently, disease pathogenesis. Moreover, our appreciation of the relationship between PMR and giant cell arteritis (GCA) has strengthened. Glucocorticoids have formed the cornerstone of the management of PMR for decades, with often protracted treatment durations and associated high cumulative steroid burden and adverse effects. However, we are now on the cusp of a new era in the management of PMR, with our therapeutic armamentarium expanding with the recent FDA approval of the interleukin -6 antagonist sarilumab for the management of refractory disease. It is an exciting time for PMR, and this review aims to explore the recent advancements in both diagnosis and management, while also providing an updated perspective on the relationship between PMR and GCA.

Keywords

Polymyalgia rheumatica / giant cell arteritis / vasculitis

References

[1] Camellino D,Girasole G,Dejaco C.Pathogenesis, diagnosis and management of polymyalgia rheumatica.Drugs Aging2019;36:1015-26

[2] Buttgereit F,Matteson EL.Polymyalgia rheumatica and giant cell arteritis: a systematic review.JAMA2016;315:2442-58

[3] Buttgereit F,Dejaco C.Polymyalgia rheumatica and giant cell arteritis.JAMA2020;324:993-4

[4] Gonzalez-Gay MA,Lopez-Diaz MJ.Epidemiology of giant cell arteritis and polymyalgia rheumatica.Arthritis Rheumatol2009;61:1454-61

[5] Raheel S,Crowson CS.Epidemiology of polymyalgia rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study.Arthritis Care Res2017;69:1282-5 PMCID:PMC5400734

[6] González-Gay MA,Castañeda S.Polymyalgia rheumatica.Lancet2017;390:1700-12

[7] Crowson CS,Myasoedova E.The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.Arthritis Rheumatol2011;63:633-9 PMCID:PMC3078757

[8] Li KJ,Turk M.A meta-analysis of the epidemiology of giant cell arteritis across time and space.Arthritis Res Ther2021;23:82 PMCID:PMC7948334

[9] Prieto-González S,García-Martínez A.Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography.Ann Rheum Dis2012;71:1170-6

[10] Ghinoi A,Nicolini A.Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study.Rheumatology2012;51:730-4

[11] Aschwanden M,Stern M.Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions.Ann Rheum Dis2010;69:1356-9

[12] Blockmans D,Vanderschueren S,Mortelmans L.Repetitive ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients.Arthritis Rheumatol2006;55:131-7

[13] Dejaco C,Buttgereit F,Dasgupta B.The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.Rheumatology2017;56:506-15

[14] Salvarani C,Iorio L.Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases?.Autoimmun Rev2023:103415

[15] Hemmig AK,Werlen L.Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data.Semin Arthritis Rheumatol2022;55:152017

[16] Burg LC,Behning C,Kermani TA.Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica - a prospective cohort study.Ther Adv Musculoskelet Dis2023;15:1759720X221149963 PMCID:PMC9909075

[17] De Miguel E,Conticini E.Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica.Rheumatology2024;63:158-64

[18] Tomelleri A,Khurshid MA.Disease stratification in GCA and PMR: state of the art and future perspectives.Nat Rev Rheumatol2023;19:446-59

[19] Dejaco C,Perel P.Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.Ann Rheum Dis2015;74:1808-17

[20] Berger CT,Aschwanden M,Rottenburger C.The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis.Swiss Med Wkly2018;148:w14661

[21] Duftner C,Sepriano A,Schmidt WA.Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations.RMD Open2018;4:e000612 PMCID:PMC5845406

[22] Rottenburger C,Imfeld S.18F-FDG PET/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches.Swiss Med Wkly2021;151:w20512

[23] Salvarani C,Hunder GG.Polymyalgia rheumatica and giant-cell arteritis.Lancet2008;372:234-45

[24] Ceccato F,Papasidero S,Rillo OL.Peripheral musculoskeletal manifestations in polymyalgia rheumatica.J Clin Rheumatol2006;12:167-71

[25] Cimmino MA,Paparo F.High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography.Rheumatology2013;52:1865-72

[26] Owen CE,Lee ST.Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica.Rheumatology2018;57:345-53

[27] Pease CT,Montague B.Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study.Rheumatology2009;48:123-7

[28] Menéndez J, Campoamor Serrano MT, Nuño Mateo FJ, Morís De La Tassa J. [Distal musculo-skeletal manifestations in rheumatic polymyalgia].Rev Clin Esp2002;202:385-7

[29] Salvarani C,Hunder GG.Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases.Arthritis Rheumatol1996;39:73-80

[30] Karmacharya P,Aryal M. RS₃PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol 2016;34:404-15. Available from: https://api.semanticscholar.org/CorpusID:32480252 [Last accessed on 12 Mar 2024]

[31] Kermani TA.Polymyalgia rheumatica.Lancet2013;381:63-72

[32] Paltta J,Pirilä L.Differential diagnostics of polymyalgia rheumatica in a university hospital in Finland.Scand J Rheumatol2023;52:689-95

[33] Mahmood SB,Padniewski J.Polymyalgia rheumatica: an updated review.Cleve Clin J Med2020;87:549-56

[34] Donskov AO,Hauge EM.An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists.Rheumatology2023;62:2797-805

[35] Gärtner M,Koban E.Immediate access rheumatology clinic: efficiency and outcomes.Ann Rheum Dis2012;71:363-8

[36] Diamantopoulos AP,Lindland A.The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?.Rheumatology2016;55:66-70

[37] Monti S,Bellis E,Montecucco C.Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse.Front Med2020;7:589794 PMCID:PMC7753207

[38] Patil P,Maw WW.Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study.Clin Exp Rheumatol2015;33:103-6

[39] Monti S,Montecucco C.A new era for the early and non-invasive diagnosis of giant cell arteritis: the use of fast-track ultrasound in clinical practice.Appl Sci2022;12:1621

[40] Frølund LL,Dam M.Fast track clinic for early diagnosis of polymyalgia rheumatica: Impact on symptom duration and prednisolone initiation.Joint Bone Spine2021;88:105185

[41] Chrysidis S,Svendsen N.The fast-track outpatient clinic significantly decreases hospitalisation rates among polymyalgia rheumatica patients.BMC Rheumatol2021;5:37 PMCID:PMC8491370

[42] Dasgupta B,Kremers HM.2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Arthritis Rheumatol2012;64:943-54

[43] Salvarani C,Niccoli L.Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.Arthritis Rheumatol2005;53:33-8

[44] Marsman DE,Boers N.Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica.Clin Exp Rheumatol2021;39:32-7

[45] Cantini F,Olivieri I.Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.Semin Arthritis Rheumatol2000;30:17-24

[46] Akiyama M,Takeuchi T.Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review.Semin Arthritis Rheumatol2020;50:521-5

[47] Bonelli M,Kerschbaumer A.Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.Ann Rheum Dis2022;81:838-44

[48] Devauchelle-Pensec V,Dernis E.Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial.JAMA2022;328:1053-62

[49] Dasgupta B,Warrington KJ.LB0006 SARILUMAB in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR).Ann Rheum Dis2022;81:210.1-1

[50] Devauchelle-Pensec V,Berthelot JM.Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.Rheumatology2018;57:666-70

[51] van der Geest KS,Rutgers A.Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.Rheumatology2015;54:1397-402

[52] Roche NE,Wagner AD,Goronzy JJ.Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis.Arthritis Rheumatol1993;36:1286-94

[53] Dasgupta B.Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis.Br J Rheumatol1990;29:456-8

[54] Mackay F.Cracking the BAFF code.Nat Rev Immunol2009;9:491-502

[55] van der Geest KS,Chalan P.Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.Arthritis Rheumatol2014;66:1927-38

[56] Tokunaga R,Naseem M.CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy.Cancer Treat Rev2018;63:40-7 PMCID:PMC5801162

[57] Deng J,Olshen RA,Weyand CM.Th17 and Th1 T-cell responses in giant cell arteritis.Circulation2010;121:906-15 PMCID:PMC2837465

[58] Brun JG,Gran JT.A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity.Scand J Rheumatol2005;34:125-8

[59] Michailidou D,Kuley R.Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica.Rheumatology2023;62:2880-6 PMCID:PMC10393430

[60] Bach M,Moore R,Nelson JL.A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis.Arthritis Rheumatol2020;72:47-56 PMCID:PMC6935396

[61] Michailidou D,Kuley R.Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis.Arthritis Res Ther2022;24:160 PMCID:PMC9241246

[62] Kuley R,Duvvuri B.N-formyl methionine peptide-mediated neutrophil activation in systemic sclerosis.Front Immunol2021;12:785275 PMCID:PMC8766990

[63] Pulsatelli L,Pignotti E.Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.Arthritis Rheumatol2008;59:1147-54

[64] McCarthy EM,Al-Mudhaffer S.Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.J Rheumatol2014;41:931-7

[65] Owen CE,Liew DFL,Scott AM.Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica.Int J Rheum Dis2021;24:56-62

[66] Conticini E,d’Alessandro M.Clinical, laboratory and ultrasonographic findings at baseline predict long-term outcome of polymyalgia rheumatica: a multicentric retrospective study : Polymyalgia rheumatica predicted by ultrasonographic findings polymyalgia rheumatica outcome predicted early by ultrasound.Intern Emerg Med2023;18:1929-39 PMCID:PMC10543828

[67] Hattori K,Kojima T.Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone.Int J Rheum Dis2020;23:1581-6

[68] Fukui S,Kobayashi S.MMP-3 can distinguish isolated PMR from PMR with GCA: a retrospective study regarding PMR and GCA in Japan.Mod Rheumatol2016;26:259-64

[69] van Sleen Y,Nielsen BD.Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica.Arthritis Res Ther2022;24:65 PMCID:PMC8900446

[70] van Sleen Y,Abdulahad WH.High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica.Rheumatology2020;59:176-84

[71] Cowley S,Harkins P.POS0716 differences in clinical and ultrasound characteristics of polymyalgia rheumatica patients with subclinical giant cell arteritis compared to those with clinical giant cell arteritis.Ann Rheum Dis2023;82:645

[72] Mackie SL,Hill CL.Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review.RMD Open2015;1:e000100

[73] Ruta S,Navarta DA.Ultrasound assessment of new onset bilateral painful shoulder in patients with polymyalgia rheumatica and rheumatoid arthritis.Clin Rheumatol2012;31:1383-7

[74] Iagnocco A,Ceccarelli F,Rutigliano IM.Musculoskeletal ultrasound in the evaluation of polymyalgia rheumatica.Med Ultrason2015;17:361-6

[75] Ottaviani S,Demaria L,Palazzo E.Ultrasound shoulder assessment of calcium pyrophosphate disease with suspected polymyalgia rheumatica.Clin Exp Rheumatol2020;38:1170-5

[76] Suzuki T,Hidaka Y.Proliferative synovitis of the shoulder bursae is a key feature for discriminating elderly onset rheumatoid arthritis mimicking polymyalgia rheumatica from polymyalgia rheumatica.Clin Med Insights Arthritis Musculoskelet Disord2017;10:1179544117745851 PMCID:PMC5724643

[77] Nawata M,Kosaka S.Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset.Mod Rheumatol2023;33:318-22

[78] Bosch P,Dejaco C.Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations.RMD Open2023;9:e003379 PMCID:PMC10450079

[79] Chrysidis S,Dejaco C.Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT large vessel vasculitis ultrasound working group.RMD Open2018;4:e000598 PMCID:PMC5976098

[80] Camellino D,Dejaco C.New insights into the role of imaging in polymyalgia rheumatica.Rheumatology2021;60:1016-33

[81] Salvarani C,Cantini F.Cervical interspinous bursitis in active polymyalgia rheumatica.Ann Rheum Dis2008;67:758-61

[82] Salvarani C,Boiardi L.Lumbar interspinous bursitis in active polymyalgia rheumatica.Clin Exp Rheumatol2013;31:526-31

[83] Kobayashi K,Kobayashi Y.Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR/ACR provisional classification criteria for polymyalgia rheumatica.Rheumatology2022;61:1185-94 PMCID:PMC8889301

[84] Huwart A,Jousse-Joulin S.Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab.Arthritis Res Ther2018;20:11 PMCID:PMC5785834

[85] Mcgonagle D,Marzo-Ortega H,Gibbon W.Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica.J Rheumatol2001;28:1837-41

[86] Marzo-Ortega H,Tan AL.Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis.Arthritis Rheumatol2007;56:3496-501

[87] Fruth M,Baraliakos X.Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica.Clin Exp Rheumatol2018;36:86-95

[88] Fruth M,Kozik J,Baraliakos X.Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica.Rheumatology2020;59:2864-71

[89] Laporte JP,Huwart A.Localized myofascial inflammation revealed by magnetic resonance imaging in recent-onset polymyalgia rheumatica and effect of tocilizumab therapy.J Rheumatol2019;46:1619-26

[90] Wakura D,Takeuchi T.Differentiation between polymyalgia rheumatica (PMR) and elderly-onset rheumatoid arthritis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: is enthesitis a new pathological lesion in PMR?.PLoS One2016;11:e0158509 PMCID:PMC4934779

[91] Rehak Z,Bortlicek Z.PET/CT imaging in polymyalgia rheumatica: praepubic (18)F-FDG uptake correlates with pectineus and adductor longus muscles enthesitis and with tenosynovitis.Radiol Oncol2017;51:8-14 PMCID:PMC5330169

[92] Camellino D.Should ¹⁸F-FDG-PET imaging be used in the diagnosis of GCA?.Nat Rev Rheumatol2019;15:388-90

[93] van der Geest KSM,Nienhuis P.Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica.Rheumatology2022;61:1072-82 PMCID:PMC8889307

[94] Brinth LS,Jensen DV,Broholm R.Diagnostic value of composite and simplified FDG-PET/CT scores in polymyalgia rheumatica and the influence of recent glucocorticoid treatment-a retrospective diagnostic cohort study.Diagnostics2023;13:514 PMCID:PMC9914179

[95] Yates M,Swords F.Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice.Clin Exp Rheumatol2017;35:1-2

[96] Partington RJ,Helliwell T,Abdul Sultan A.Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study.Ann Rheum Dis2018;77:1750-6

[97] Floris A,Chessa E.Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis.Clin Rheumatol2022;41:19-31 PMCID:PMC8724087

[98] Sattui SE,Wan Z,Domsic RT.Treatment of polymyalgia rheumatica by rheumatology providers: analysis from the American College of Rheumatology RISE registry.Arthritis Care Res2024;76:259-64

[99] Salvarani C,Olivieri I.Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study.J Rheumatol2000;27:1470-6

[100] Dasgupta B,Panayi GS.An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.Br J Rheumatol1998;37:189-95

[101] Gabriel SE,Salvarani C,Hunder GG.Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica.Arthritis Rheumatol1997;40:1873-8

[102] Ferraccioli G,De Vita S,Bartoli E.Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.J Rheumatol1996;23:624-8

[103] Caporali R,Ferraccioli G.Systemic Vasculitis Study Group of the Italian Society for RheumatologyPrednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.Ann Intern Med2004;141:493-500

[104] van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?.Ann Rheum Dis1996;55:218-23 PMCID:PMC1010141

[105] Marsman DE,den Broeder N,van der Maas A.PolyMyalgia rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.Trials2022;23:318 PMCID:PMC9012047

[106] De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.Ann Rheum Dis1986;45:136-8 PMCID:PMC1001834

[107] Adizie T,Dharmapaliah C,Dasgupta B.Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series.Int J Clin Pract2012;66:906-9

[108] Diamantopoulos AP,Myklebust G.Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.Biomed Res Int2013;2013:120638 PMCID:PMC3784071

[109] Spiera RF,Warrington KJ.Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper.N Engl J Med2023;389:1263-72

[110] Tuckwell K,Dimonaco S.Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial.Semin Arthritis Rheum2017;46:657-64

[111] Salvarani C,Manzini C.Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.Ann Intern Med2007;146:631-9

[112] Marsman DE,van den Hoogen FHJ,van der Maas A.Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial.Lancet Rheumatol2021;3:e758-66

[113] Bolhuis TE,den Broeder AA,van der Maas A.1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.Lancet Rheumatol2023;5:e208-14

[114] Harkins P,Swales C,Conway R.Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis.Int J Rheum Dis2023;26:31-42 PMCID:PMC10092437

[115] McLornan DP,Gotlib J.Current and future status of JAK inhibitors.Lancet2021;398:803-16

[116] Ma X,Wu J.Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial.PLoS Med2023;20:e1004249 PMCID:PMC10309604